Greenwich LifeSciences, Inc. (GLSI)Â
NASDAQ$11.11
Market Cap
$146.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
90 of 922
Rank in Industry
66 of 526
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GLSI Insider Trading Activity
GLSI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $3,009,702 | 18 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Patel Snehal | CEO and CFO | 14 | $2.95M | 0 | $0 | $2.95M |
| Thompson Jaye | VP Clinical Reg Affairs | 4 | $55,140 | 0 | $0 | $55,140 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Insider Activity of Greenwich LifeSciences, Inc.
Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $3.01M and sold $0 worth of Greenwich LifeSciences, Inc. stock.
On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.45M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $2.95M. Thompson Jaye (VP Clinical Reg Affairs) — $55,140.
The last purchase of 2,500 shares for transaction amount of $31,275 was made by Patel Snehal (CEO and CFO) on 2025‑01‑10.
List of Insider Buy and Sell Transactions, Greenwich LifeSciences, Inc.
| 2025-01-10 | Patel Snehal | CEO and CFO | 2,500 0.0191% | $12.51 | $31,275 | -1.29% | ||
| 2025-01-07 | Patel Snehal | CEO and CFO | 1,800 0.0138% | $13.75 | $24,750 | -11.37% | ||
| 2025-01-06 | Patel Snehal | CEO and CFO | 1,100 0.0084% | $13.31 | $14,641 | -6.56% | ||
| 2025-01-03 | Patel Snehal | CEO and CFO | 3,400 0.0253% | $12.95 | $44,030 | -4.85% | ||
| 2025-01-02 | Patel Snehal | CEO and CFO | 2,000 0.0154% | $11.97 | $23,940 | +4.43% | ||
| 2024-12-31 | Patel Snehal | CEO and CFO | 2,400 0.0181% | $11.36 | $27,264 | +9.13% | ||
| 2024-12-30 | Patel Snehal | CEO and CFO | 3,200 0.0235% | $11.12 | $35,584 | +12.28% | ||
| 2024-11-21 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.0077% | $12.91 | $12,910 | -4.43% | ||
| 2024-09-26 | Patel Snehal | CEO and CFO | 1,500 0.0114% | $14.63 | $21,945 | -9.50% | ||
| 2024-08-12 | Thompson Jaye | VP Clinical Reg Affairs | 800 0.0065% | $13.85 | $11,080 | -0.22% | ||
| 2024-08-06 | Patel Snehal | CEO and CFO | 2,000 0.0151% | $13.81 | $27,620 | -5.68% | ||
| 2024-08-05 | Patel Snehal | CEO and CFO | 5,500 0.0424% | $13.18 | $72,490 | +0.91% | ||
| 2024-08-02 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.0082% | $15.15 | $15,150 | -6.86% | ||
| 2024-07-23 | Patel Snehal | CEO and CFO | 1,500 0.0115% | $15.89 | $23,835 | -16.24% | ||
| 2024-07-18 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.008% | $16.00 | $16,000 | -13.39% | ||
| 2024-06-13 | Patel Snehal | CEO and CFO | 174,825 1.3679% | $14.30 | $2.5M | -8.48% | ||
| 2024-04-01 | Patel Snehal | CEO and CFO | 3,000 0.0234% | $19.08 | $57,240 | -28.26% | ||
| 2024-03-22 | Patel Snehal | CEO and CFO | 2,500 0.0198% | $19.98 | $49,950 | -30.33% | ||
| 2024-03-20 | Patel Snehal | CEO and CFO | 1,500 0.0112% | $17.68 | $26,520 | -25.52% | ||
| 2024-03-05 | Patel Snehal | CEO and CFO | 30,500 0.2372% | $12.49 | $380,945 | +10.18% |
Total: 101
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Patel Snehal | CEO and CFO | 5552502 42.2414% | $61.69M | 67 | 0 | +3.47% |
| Thompson Jaye | VP Clinical Reg Affairs | 264148 2.0095% | $2.93M | 21 | 0 | <0.0001% |
| McWilliams David | director | 620301 4.719% | $6.89M | 3 | 0 | <0.0001% |
| Hallock Kenneth | director | 397304 3.0225% | $4.41M | 4 | 0 | <0.0001% |
| Rothe Eric | director | 313226 2.3829% | $3.48M | 1 | 0 | |
| Daugherty Frank Joseph | Chief Medical Officer | 90121 0.6856% | $1M | 5 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $137.19M | |
$860,541,348 | 82 | -5.10% | $131.29M | |
Greenwich LifeSciences, Inc. (GLSI) | $2,951,087 | 73 | -5.15% | $146.04M |
$909,129 | 37 | 42.19% | $132.46M | |
$64,487,106 | 32 | -22.92% | $124.89M | |
$79,019,806 | 27 | 7.24% | $162.07M | |
$40,617,659 | 23 | 2.15% | $125.21M | |
$6,915,275 | 21 | -32.61% | $169.13M | |
$91,870,774 | 13 | 3.64% | $150.12M | |
$10,143,329 | 12 | 11.84% | $134.61M | |
$2,788,839 | 12 | 6.73% | $159.32M | |
$19,659,196 | 11 | 21.81% | $170.03M | |
$135,589,307 | 10 | 32.46% | $136.12M | |
$556,839 | 5 | 13.42% | $150.5M | |
$63,981 | 5 | -11.55% | $164.39M | |
$32,289,200 | 3 | -5.46% | $133.77M | |
$47,368,750 | 2 | -21.95% | $166.89M | |
$1,250 | 1 | 278.21% | $135.74M | |
$879,499 | 1 | 28.50% | $157.7M |
GLSI Institutional Investors: Active Positions
| Increased Positions | 22 | +73.33% | 66,924 | +5.93% |
| Decreased Positions | 8 | -26.67% | 24,189 | -2.14% |
| New Positions | 6 | New | 21,526 | New |
| Sold Out Positions | 3 | Sold Out | 10,640 | Sold Out |
| Total Postitions | 44 | +46.67% | 1M | +3.78% |
GLSI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $4,294.00 | 2.75% | 357,844 | +7,700 | +2.2% | 2024-12-31 |
| Vanguard Group Inc | $3,300.00 | 2.12% | 274,991 | +1,466 | +0.54% | 2024-12-31 |
| Geode Capital Management, Llc | $1,609.00 | 1.03% | 134,071 | +521 | +0.39% | 2024-12-31 |
| Northern Trust Corp | $1,049.00 | 0.67% | 87,423 | +12,923 | +17.35% | 2024-12-31 |
| Credit Agricole S A | $1,044.00 | 0.67% | 87,000 | 0 | 0% | 2024-12-31 |
| State Street Corp | $878.00 | 0.56% | 73,208 | +1,800 | +2.52% | 2024-12-31 |
| Renaissance Technologies Llc | $272.00 | 0.18% | 22,700 | -9,800 | -30.15% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $197.00 | 0.13% | 16,455 | 0 | 0% | 2024-12-31 |
| Goldman Sachs Group Inc | $181.00 | 0.12% | 15,070 | +15,070 | New | 2024-12-31 |
| Morgan Stanley | $165.00 | 0.11% | 13,774 | -3,257 | -19.12% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.